We want to improve care for chronic inflammatory diseases

I lead a team of epidemiologists, statisticians, and clinical researchers who use Sweden's unique health data infrastructure to study diseases and treatments in real-world clinical practice. We focus particularly on inflammatory diseases such as rheumatoid arthritis and multiple sclerosis, with a simple goal: to generate evidence that helps patients, clinicians, and policymakers make better decisions.

Registry-based clinical epidemiology

A central part of our research is the use of large healthcare and population-based registers to follow patients over time. This allows us to study both the natural course of diseases and how different treatments perform in routine clinical practice.

Asking better questions

We are almost as interested in the methods as in the findings themselves. The rapid development of electronic health records, quality registers, and other data sources creates new opportunities to answer increasingly complex questions about disease progression, treatment effectiveness, and patient safety. By establishing new research databases and remaining at the forefront of statistical and epidemiological methods, we aim to provide clearer and more reliable answers to questions that matter to patients, healthcare professionals, and society.

Off-Label treatment for MS

One successful example is our work on the off-label use of rituximab in multiple sclerosis. In collaboration with neurologists and researchers at the Department of Clinical Neuroscience, we have shown that the treatment is highly effective in preventing relapses, while also highlighting important risks, particularly infections, that need to be considered. Our findings have contributed to both national and international discussions on the evidence base for off-label treatment.

Research Environment and Collaborations

Our group, which is part of the Division of Clinical Epidemiology, includes an assistant professor, two postdoctoral researchers, two doctoral students, and a statistician. We enjoy combining methodological development with clinically relevant research questions and welcome collaborations with researchers who are interested in using health data to better understand and improve healthcare.